New combo therapy shows promise for diabetic eye damage
NCT ID NCT07230184
First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tested whether adding a second drug (B55R2) to a standard treatment (B55R1) works better for people with non-proliferative diabetic retinopathy, a common eye problem from diabetes. 52 adults with mild to severe disease received either the combo or the single drug for 24 weeks. The main goal was to see if the combo could reduce hard exudates (fatty deposits) in the eye more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-PROLIFERATIVE DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AJU Pharm Co., Ltd.
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.